deltatrials
Completed PHASE1 NCT01519817

Cancer Vaccine Targeting Brachyury Protein in Tumors

An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express Brachyury Protein in Adults With Solid Tumors

Sponsor: National Cancer Institute (NCI)

Conditions Adenocarcinoma Colon Neoplasms Malignant Solid Tumors Neoplasms
Interventions GI-6301 (Yeast Brachyury Vaccine)
Updated 8 times since 2017 Last updated: Jan 2, 2018 Started: Jan 5, 2012 Primary completion: Mar 3, 2016 Completion: Sep 1, 2016

Listed as NCT01519817, this PHASE1 trial focuses on Adenocarcinoma and Colon Neoplasms and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 8 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Feb 2018 — Jun 2018 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 3 earlier versions

  1. Sep 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE1

  2. Feb 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE1

  3. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States